Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Alx Oncology Holdings Inc (ALXO)

Alx Oncology Holdings Inc (ALXO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 74,821
  • Shares Outstanding, K 54,218
  • Annual Sales, $ 0 K
  • Annual Income, $ -134,850 K
  • EBIT $ -112 M
  • EBITDA $ -115 M
  • 60-Month Beta 1.23
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.46

Options Overview Details

View History
  • Implied Volatility 297.05% ( -198.27%)
  • Historical Volatility 126.31%
  • IV Percentile 63%
  • IV Rank 24.94%
  • IV High 1,013.27% on 06/11/25
  • IV Low 59.06% on 05/08/25
  • Put/Call Vol Ratio 0.00
  • Today's Volume 5
  • Volume Avg (30-Day) 452
  • Put/Call OI Ratio 1.14
  • Today's Open Interest 12,151
  • Open Int (30-Day) 6,849

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.33
  • Number of Estimates 2
  • High Estimate -0.25
  • Low Estimate -0.40
  • Prior Year -0.55
  • Growth Rate Est. (year over year) +40.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0500 +31.43%
on 11/07/25
1.9000 -27.37%
on 10/24/25
-0.3200 (-18.82%)
since 10/14/25
3-Month
0.6245 +120.98%
on 08/15/25
2.2700 -39.21%
on 10/06/25
+0.7250 (+110.69%)
since 08/14/25
52-Week
0.4040 +241.58%
on 06/27/25
2.2700 -39.21%
on 10/06/25
+0.0500 (+3.76%)
since 11/14/24

Most Recent Stories

More News
ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update

ASPEN-06 data to be presented at SITC demonstrates that evorpacept drove durable clinical benefit across all efficacy measures in HER2+ gastric cancer patients with high CD47 expression Phase...

ALXO : 1.3800 (+13.11%)
ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline...

ALXO : 1.3800 (+13.11%)
ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference

-Two poster presentations showcase best- and first-in-class potential of ALX2004, a novel, antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors -Robust body of preclinical...

ALXO : 1.3800 (+13.11%)
ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Company will share data demonstrating CD47 overexpression as key predictive biomarker for response with the Company’s lead candidate, evorpacept, in HER2+ gastric cancer SOUTH SAN FRANCISCO, Calif.,...

ALXO : 1.3800 (+13.11%)
ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer

Dr. Barbara Klencke is an accomplished clinical leader with a distinguished track record in oncology drug development who currently serves on the Company’s Board of Directors and will step down from...

ALXO : 1.3800 (+13.11%)
FDA Accelerates Cancer Drug Pipeline as Market Momentum Surges Past $400B

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The FDA's unprecedented accelerated approval pace through August 2025 has delivered breakthrough treatments...

ONCY : 1.0400 (-3.70%)
IOVA : 2.47 (+2.49%)
OLMA : 8.40 (+5.79%)
ALXO : 1.3800 (+13.11%)
BNTX : 103.09 (-0.76%)
FDA Fast-Track Cancer Treatments Drive Market Surge as Innovations Accelerate

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Cancer treatment is experiencing unprecedented momentum as the FDA approved breakthrough therapies for...

ONCY : 1.0400 (-3.70%)
NVCR : 11.32 (-0.53%)
IMRX : 6.35 (-1.55%)
LLY : 1,025.28 (+0.38%)
ALXO : 1.3800 (+13.11%)
ALX Oncology to Participate in Upcoming Investor Conferences in September

SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline...

ALXO : 1.3800 (+13.11%)
ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors

- A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the therapeutic...

ALXO : 1.3800 (+13.11%)
ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update

– Data from ASPEN-06 trial highlights CD47 expression as a key predictive biomarker of greater response to evorpacept in HER2+ Gastric Cancer; updated data to be presented at a medical conference in...

ALXO : 1.3800 (+13.11%)

Business Summary

ALX Oncology Holdings Inc.is a clinical-stage immuno-oncology company. It focuses on developing therapies for patients fighting cancer. The company's product candidate consist ALX148, which is in clinical stage. ALX Oncology Holdings Inc.is based in Burlingame, California.

See More

Key Turning Points

3rd Resistance Point 1.7992
2nd Resistance Point 1.6346
1st Resistance Point 1.5073
Last Price 1.3800
1st Support Level 1.2154
2nd Support Level 1.0508
3rd Support Level 0.9235

See More

52-Week High 2.2700
Fibonacci 61.8% 1.5572
Last Price 1.3800
Fibonacci 50% 1.3370
Fibonacci 38.2% 1.1168
52-Week Low 0.4040

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar